Analysts expect Nasus Pharma Ltd to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 |
Analysts expect Nasus Pharma Ltd to report earnings per share of -1.18 for 2026, against a range of -1.30 to -1.06. The most recent reported year, 2025, came in at -0.73, a 4.3% miss against the -0.70 consensus.
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| Reported (Actual) | -0.73 | - | - | ||
| High Estimate | -0.64 | -1.06 | -1.02 | ||
| Low Estimate | -0.76 | -1.30 | -1.12 | ||
| Consensus Estimate | -0.70 | -1.18 | -1.07 |